Pleural Dynamics began with the inspiration that there must be a better way to manage recurrent pleural effusions.  The company was founded in 2020 by an Interventional Pulmonologist Inventor/Entrepreneur and a Seasoned Engineering Leader who have spent the last 25+ years addressing unmet clinical needs through medical practice and novel medical device innovation.

 

The Automatic Continuous Effusion Shunt is U.S. FDA cleared in 2023.  In parallel with commercial launch, a post-market physician preference study, The ACES Study for Aseptic Pleural Effusion (NCT06210685) has been underway to gather clinical data.  Clinical experience to date is encouraging and has demonstrated implantation success in all patients, significant reduction in effusion volume, and a low rate of adverse events. Enrollment in the study is nearly complete and results are anticipated to be published in 2025.